Yazarlar : Lu S, Xu Y, Mu Q

Yayın : Leuk Lymphoma

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/risk-hepatitis-b-virus-reactivation-and-role-antiviral-prophylaxis-hepatitis-b-surface-antigen-negat?tsid=5

Konu : Enfeksiyon

Literatür İçeriği :  ABSTRACT The risk factors and the role of prophylactic antiviral therapy of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg) negative/hepatitis B core antibody (HBcAb) positive patients remain controversial. We reviewed 629 patients with diffuse large B cell lymphoma (DLBCL). Among 629 patients, 150 of 246 patients with resolved HBV (HBsAg negative and HBcAb positive) were treated with rituximab combined therapy. Among these 150 patients, none of 104 patients (0.0%) who were hepatitis B surface antibody (HBsAb) positive experienced HBV reactivation versus four of 46 patients (8.7%) who were HBsAb negative (p=0.008); one of 113 patients (0.9%) with International Prognostic Index (IPI) 0-2 suffered HBV reactivation versus three of the remaining 37 patients (8.1%) with IPI 3-5 (p=0.047). HBsAb and IPI are potential risk factors of HBV reactivation. The use of prophylactic agents may not be recommended for these patients until the occurrence of HBV reactivation.

Literatür Arşivi